CHRONIC LOWER LIMB ISCHEMIA: FUTURE OF CELL THERAPY AND GENETICALLY ENGINEERED TECHNOLOGIES APPLIANCE
The article presents an analysis of published data on using cell therapy and genetically engineered technologies for stimulating angiogenesis in case of chronic lower limb ischemia. The technologies include use of growth factors, vector-mediated transgene transfer, mesenchymal and hematopoietic stem cells. The clinical studies outcomes are considered and the therapy near and remote results are assessed. The data presented demonstrate the used biotherapeutical approaches safety and their efficiency in most clinical trials based on assessment of early treatment responses for 3—6 months of observations. Additional clinical studies are necessary in order to assess the chronic lower limb ischemia biotherapy late effects.